OTC Markets OTCPK - Delayed Quote USD

Merck KGaA (MKGAF)

Compare
142.08
-3.35
(-2.30%)
As of January 10 at 3:55:08 PM EST. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
20,963,000.00
20,993,000.00
22,232,000.00
19,687,000.00
17,534,000.00
Cost of Revenue
8,679,000.00
8,600,000.00
8,527,000.00
7,351,000.00
6,835,000.00
Gross Profit
12,284,000.00
12,393,000.00
13,705,000.00
12,336,000.00
10,699,000.00
Operating Expense
8,913,000.00
8,816,000.00
8,953,000.00
8,127,000.00
7,889,000.00
Operating Income
3,371,000.00
3,577,000.00
4,752,000.00
4,209,000.00
2,810,000.00
Net Non Operating Interest Income Expense
-100,000.00
-151,000.00
-157,000.00
-229,000.00
-353,000.00
Pretax Income
3,368,000.00
3,484,000.00
4,287,000.00
3,924,000.00
2,630,000.00
Tax Provision
664,000.00
650,000.00
948,000.00
859,000.00
637,000.00
Net Income Common Stockholders
2,696,000.00
2,824,000.00
3,326,000.00
3,055,000.00
1,987,000.00
Diluted NI Available to Com Stockholders
2,696,000.00
2,824,000.00
3,326,000.00
3,055,000.00
1,987,000.00
Basic EPS
6.19
6.49
7.65
7.03
4.57
Diluted EPS
6.19
6.49
7.65
7.03
4.57
Basic Average Shares
435,144.21
434,777.88
434,777.88
434,777.88
434,777.88
Diluted Average Shares
435,144.21
434,777.88
434,777.88
434,777.88
434,777.88
Total Operating Income as Reported
3,442,000.00
3,609,000.00
4,474,000.00
4,179,000.00
2,985,000.00
Total Expenses
17,592,000.00
17,416,000.00
17,480,000.00
15,478,000.00
14,724,000.00
Net Income from Continuing & Discontinued Operation
2,696,000.00
2,824,000.00
3,326,000.00
3,055,000.00
1,987,000.00
Normalized Income
2,654,251.78
2,813,431.00
3,512,993.00
3,069,839.00
1,811,949.43
Interest Income
200,000.00
172,000.00
71,000.00
46,000.00
39,000.00
Interest Expense
298,000.00
321,000.00
235,000.00
272,000.00
387,000.00
Net Interest Income
-100,000.00
-151,000.00
-157,000.00
-229,000.00
-353,000.00
EBIT
3,666,000.00
3,805,000.00
4,522,000.00
4,196,000.00
3,017,000.00
EBITDA
5,756,000.00
5,685,000.00
6,552,000.00
5,963,000.00
4,955,000.00
Reconciled Cost of Revenue
8,679,000.00
8,600,000.00
8,527,000.00
7,351,000.00
6,835,000.00
Reconciled Depreciation
2,090,000.00
1,880,000.00
2,030,000.00
1,767,000.00
1,938,000.00
Net Income from Continuing Operation Net Minority Interest
2,696,000.00
2,824,000.00
3,326,000.00
3,055,000.00
1,987,000.00
Total Unusual Items Excluding Goodwill
52,000.00
13,000.00
-237,000.00
-19,000.00
231,000.00
Total Unusual Items
52,000.00
13,000.00
-237,000.00
-19,000.00
231,000.00
Normalized EBITDA
5,704,000.00
5,672,000.00
6,789,000.00
5,982,000.00
4,724,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
10,251.78
2,431.00
-50,007.00
-4,161.00
55,949.43
12/31/2020 - 8/3/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

29A.SG Amphastar Pharmaceuticals Inc
36.20
+3.08%
 
068760.KQ Celltrion Pharm, Inc.
56,300.00
-1.05%
 
0ET.MU Esperion Therapeutics Inc
2.1980
+2.66%
 
R9U2.F Green Thumb Industries Inc.
7.20
-2.90%
 
SHMN SOHM, Inc.
0.0007
0.00%
 
CEL.L Celadon Pharmaceuticals Plc
16.00
0.00%
 
DLTNF Delta 9 Cannabis Inc.
0.0080
+14.29%
 
TEV.F Teva Pharmaceutical Industries Limited
20.20
-0.49%
 
SFZN.SW Siegfried Holding AG
979.00
-0.91%
 
KLAR.ST Klaria Pharma Holding AB (publ.)
0.6700
+123.33%